niacin has been researched along with Innate Inflammatory Response in 63 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although studies have reported direct inhibition of inflammatory pathways with niacin, the effect of niacin on arterial wall inflammation remains unknown." | 9.20 | A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. ( Alavi, A; deGoma, EM; Dunbar, RL; Litt, HI; Mehta, NN; Mohler, ER; Pollan, L; Rader, DJ; Saboury, B; Salavati, A; Schoen, M; Shinohara, RT; Torigian, DA; Woo, J, 2015) |
| "In this study, niacin was added to existing therapy for 3 months in 54 subjects with stable coronary artery disease." | 9.12 | Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. ( Dave, DM; Karas, RH; Kimmelstiel, CD; Kuvin, JT; Mooney, P; Patel, AR; Sliney, KA, 2006) |
| "Niacin is an agent that significantly increases high-density lipoprotein cholesterol (HDL-C), but its effects on surrogate markers of atherosclerosis and inflammatory markers are less clear." | 9.12 | The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. ( Hammoud, R; Khan, BV; Nagamia, S; Oguchi, A; Thoenes, M; Umpierrez, GE; Vaccari, CS, 2007) |
| "The identification of the GPR109A receptor has promoted a greater insight into niacin's mechanism of action, with demonstrated beneficial effects on endothelial function and inflammation, in addition to its lipid modulation role." | 8.87 | Effects of niacin on atherosclerosis and vascular function. ( Choudhury, RP; Digby, JE; Ruparelia, N, 2011) |
| "Dietary SFA (combined with niacin) promote postprandial excursions of circulating IL-6, IL-1β, TNF-α and CD14/CCR2-rich monocytes with a pro-inflammatory M1-like phenotype, particularly in individuals with metabolic syndrome." | 8.31 | Immediate-release niacin and a monounsaturated fatty acid-rich meal on postprandial inflammation and monocyte characteristics in men with metabolic syndrome. ( Abia, R; Bermudez, B; Del Carmen Millan-Linares, M; Del Carmen Naranjo, M; Jaramillo-Carmona, SM; Lopez, S; Montserrat-de la Paz, S; Muriana, FJG; Rivas-Dominguez, A, 2023) |
| "BACKGROUND Niacin is a broad-spectrum lipid-regulating drug used for the clinical therapy of atherosclerosis; however, the mechanisms by which niacin ameliorates atherosclerosis are not clear." | 7.81 | Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells. ( Guo, L; Huang, C; Liu, H; Shu, L; Su, G; Sun, G; Xu, J; Zhang, J, 2015) |
| "To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels." | 7.76 | Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. ( Barter, PJ; Charlton, F; Rye, KA; Witting, P; Wu, BJ; Yan, L, 2010) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 6.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 enzymatic product bilirubin." | 5.38 | Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. ( Barter, PJ; Chen, K; Rye, KA; Wu, BJ, 2012) |
| "Taurine has been shown to protect against lung injury induced by various oxidants including ozone, nitrogen dioxide, amiodarone, and paraquat and to protect against bleomycin-induced lung injury in combination with niacin." | 5.35 | Protection of bleomycin-induced fibrosis and inflammation by taurine. ( Gordon, RE; Park, E; Park, SY; Schuller-Levis, G; Wang, C, 2009) |
| "Although studies have reported direct inhibition of inflammatory pathways with niacin, the effect of niacin on arterial wall inflammation remains unknown." | 5.20 | A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. ( Alavi, A; deGoma, EM; Dunbar, RL; Litt, HI; Mehta, NN; Mohler, ER; Pollan, L; Rader, DJ; Saboury, B; Salavati, A; Schoen, M; Shinohara, RT; Torigian, DA; Woo, J, 2015) |
| "In this study, niacin was added to existing therapy for 3 months in 54 subjects with stable coronary artery disease." | 5.12 | Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. ( Dave, DM; Karas, RH; Kimmelstiel, CD; Kuvin, JT; Mooney, P; Patel, AR; Sliney, KA, 2006) |
| "Niacin is an agent that significantly increases high-density lipoprotein cholesterol (HDL-C), but its effects on surrogate markers of atherosclerosis and inflammatory markers are less clear." | 5.12 | The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. ( Hammoud, R; Khan, BV; Nagamia, S; Oguchi, A; Thoenes, M; Umpierrez, GE; Vaccari, CS, 2007) |
| "The identification of the GPR109A receptor has promoted a greater insight into niacin's mechanism of action, with demonstrated beneficial effects on endothelial function and inflammation, in addition to its lipid modulation role." | 4.87 | Effects of niacin on atherosclerosis and vascular function. ( Choudhury, RP; Digby, JE; Ruparelia, N, 2011) |
| "Hydroxycarboxylic acid receptor 2 (HCAR2), modulated by endogenous ketone body β-hydroxybutyrate and exogenous niacin, is a promising therapeutic target for inflammation-related diseases." | 4.31 | Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation. ( Cheng, L; Fu, H; Fu, P; Hu, H; Li, Z; Liu, Y; Ma, L; Shao, Z; Shen, C; Tian, X; Wang, B; Wang, C; Wang, H; Wu, C; Yan, W; Yang, S; Yu, J; Zhao, C, 2023) |
| "Dietary SFA (combined with niacin) promote postprandial excursions of circulating IL-6, IL-1β, TNF-α and CD14/CCR2-rich monocytes with a pro-inflammatory M1-like phenotype, particularly in individuals with metabolic syndrome." | 4.31 | Immediate-release niacin and a monounsaturated fatty acid-rich meal on postprandial inflammation and monocyte characteristics in men with metabolic syndrome. ( Abia, R; Bermudez, B; Del Carmen Millan-Linares, M; Del Carmen Naranjo, M; Jaramillo-Carmona, SM; Lopez, S; Montserrat-de la Paz, S; Muriana, FJG; Rivas-Dominguez, A, 2023) |
| " The effects of vitamin D, alone or in combination with niacin, on endothelial cell (EC) angiogenic function and on revascularization in obese animals with peripheral ischemia are unknown." | 3.91 | Vitamin D intervention does not improve vascular regeneration in diet-induced obese male mice with peripheral ischemia. ( Borradaile, NM; Nong, Z; Park, C; Peters, KM; Pickering, JG; Sawyez, CG; Sutherland, BG; Wilson, RB; Yin, H; Zhang, R, 2019) |
| "BACKGROUND Niacin is a broad-spectrum lipid-regulating drug used for the clinical therapy of atherosclerosis; however, the mechanisms by which niacin ameliorates atherosclerosis are not clear." | 3.81 | Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells. ( Guo, L; Huang, C; Liu, H; Shu, L; Su, G; Sun, G; Xu, J; Zhang, J, 2015) |
| "The Genetics of Evoked Responses to Niacin and Endotoxemia (GENE) study was designed to investigate regulation of inflammatory and metabolic responses during low-grade endotoxemia (LPS 1 ng/kg intravenously) in healthy individuals (median age 24, IQR=7) of European (EA; n=193, 47% female) and African ancestry (AA; n=101, 59% female)." | 3.79 | Race and gender variation in response to evoked inflammation. ( Ferguson, JF; Gadi, R; Master, SR; Mehta, NN; Mulvey, CK; Nijjar, PS; Patel, PN; Propert, KJ; Reilly, MP; Shah, R; Shah, RY; Usman, HM, 2013) |
| " The nutraceutical GEA, ALA, niacin, and NA completely prevented the SFA-induced disturbances of BBB and normalized the measures of neurovascular inflammation and oxidative stress." | 3.79 | Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood-brain barrier function in wild-type mice. ( Giles, C; Lam, V; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2013) |
| "To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels." | 3.76 | Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. ( Barter, PJ; Charlton, F; Rye, KA; Witting, P; Wu, BJ; Yan, L, 2010) |
| "To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated inflammation in macrophages." | 3.76 | Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. ( Fisher, T; Hubbard, B; Kling, J; Li, H; Pagler, T; Sparrow, CP; Taggart, AK; Tall, AR; Yvan-Charvet, L, 2010) |
| "Pellagra is a curable dietary illness that unchecked leads to dementia, diarrhoea, dermatitis and death due to lack of the precursors for NAD(H)." | 3.74 | Pellagra: A clue as to why energy failure causes diseases? ( Ramsden, DB; Williams, AC, 2007) |
| "Combined treatment with taurine and niacin suppressed BL-induced inflammation and almost completely abrogated pulmonary fibrosis in hamsters." | 3.68 | Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin. ( Giri, SN; Hyde, DM; Wang, Q, 1992) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 2.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Inflammation is a risk factor for the onset and progression of schizophrenia, and dietary factors are related to chronic inflammation." | 1.62 | Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea. ( Cha, HY; Kim, SW; Yang, SJ, 2021) |
| "Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 enzymatic product bilirubin." | 1.38 | Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. ( Barter, PJ; Chen, K; Rye, KA; Wu, BJ, 2012) |
| " In conclusion, these data suggest that long-term administration of nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions, which are independent of its lipid-modifying actions." | 1.37 | Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. ( Albrecht, C; Bea, F; Blessing, E; Buttler, A; Holzhäuser, E; Katus, HA; Preusch, MR; Zhou, Q, 2011) |
| "Chronic obstructive pulmonary disease (COPD) is a chronic progressive inflammatory disease characterized by elevated lung neutrophils, macrophages, and CD8+ T lymphocytes and mucus hypersecretion." | 1.36 | Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung. ( Baccei, CS; Bain, G; Broadhead, AR; Coate, H; Evans, JF; Fagan, P; Hutchinson, JH; King, CD; Lorrain, DS; Prasit, P; Prodanovich, P; Santini, AM; Scott, JM; Stearns, BA; Stebbins, KJ; Stock, NS; Truong, YP, 2010) |
| "Taurine has been shown to protect against lung injury induced by various oxidants including ozone, nitrogen dioxide, amiodarone, and paraquat and to protect against bleomycin-induced lung injury in combination with niacin." | 1.35 | Protection of bleomycin-induced fibrosis and inflammation by taurine. ( Gordon, RE; Park, E; Park, SY; Schuller-Levis, G; Wang, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (20.63) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 14 (22.22) | 29.6817 |
| 2010's | 28 (44.44) | 24.3611 |
| 2020's | 6 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Guo, W | 1 |
| Li, W | 1 |
| Su, Y | 1 |
| Liu, S | 1 |
| Kan, X | 1 |
| Ran, X | 1 |
| Cao, Y | 1 |
| Fu, S | 1 |
| Liu, J | 1 |
| Zhao, C | 1 |
| Wang, H | 1 |
| Liu, Y | 1 |
| Cheng, L | 1 |
| Wang, B | 1 |
| Tian, X | 1 |
| Fu, H | 1 |
| Wu, C | 1 |
| Li, Z | 1 |
| Shen, C | 1 |
| Yu, J | 1 |
| Yang, S | 2 |
| Hu, H | 1 |
| Fu, P | 1 |
| Ma, L | 1 |
| Wang, C | 2 |
| Yan, W | 1 |
| Shao, Z | 1 |
| Montserrat-de la Paz, S | 2 |
| Del Carmen Naranjo, M | 1 |
| Lopez, S | 2 |
| Del Carmen Millan-Linares, M | 1 |
| Rivas-Dominguez, A | 1 |
| Jaramillo-Carmona, SM | 1 |
| Abia, R | 2 |
| Muriana, FJG | 1 |
| Bermudez, B | 2 |
| Deng, X | 1 |
| Zhou, S | 1 |
| Hu, Z | 1 |
| Gong, F | 1 |
| Zhang, J | 2 |
| Zhou, C | 1 |
| Lan, W | 1 |
| Gao, X | 1 |
| Huang, Y | 1 |
| Giri, B | 1 |
| Belanger, K | 1 |
| Seamon, M | 1 |
| Bradley, E | 1 |
| Purohit, S | 1 |
| Chong, R | 1 |
| Morgan, JC | 1 |
| Baban, B | 1 |
| Wakade, C | 1 |
| Garrido-Suárez, BB | 1 |
| Garrido, G | 1 |
| Castro-Labrada, M | 1 |
| Merino, N | 1 |
| Valdés, O | 1 |
| Pardo, Z | 1 |
| Ochoa-Rodríguez, E | 1 |
| Verdecia-Reyes, Y | 1 |
| Delgado-Hernández, R | 1 |
| Godoy-Figueiredo, J | 1 |
| Ferreira, SH | 1 |
| Cha, HY | 1 |
| Yang, SJ | 1 |
| Kim, SW | 1 |
| Salem, HA | 1 |
| Wadie, W | 1 |
| El-Bahy, AAZ | 1 |
| Aboulmagd, YM | 1 |
| Zaki, M | 1 |
| Mandrika, I | 1 |
| Tilgase, A | 1 |
| Petrovska, R | 1 |
| Klovins, J | 1 |
| Peters, KM | 1 |
| Zhang, R | 1 |
| Park, C | 1 |
| Nong, Z | 1 |
| Yin, H | 1 |
| Wilson, RB | 1 |
| Sutherland, BG | 1 |
| Sawyez, CG | 1 |
| Pickering, JG | 1 |
| Borradaile, NM | 1 |
| Ferguson, JF | 1 |
| Patel, PN | 1 |
| Shah, RY | 1 |
| Mulvey, CK | 1 |
| Gadi, R | 1 |
| Nijjar, PS | 1 |
| Usman, HM | 1 |
| Mehta, NN | 2 |
| Shah, R | 1 |
| Master, SR | 1 |
| Propert, KJ | 1 |
| Reilly, MP | 1 |
| Ferreira, RG | 1 |
| Matsui, TC | 1 |
| Gomides, LF | 1 |
| Godin, AM | 1 |
| Menezes, GB | 1 |
| de Matos Coelho, M | 1 |
| Klein, A | 1 |
| Takechi, R | 1 |
| Pallebage-Gamarallage, MM | 1 |
| Lam, V | 1 |
| Giles, C | 1 |
| Mamo, JC | 1 |
| Hafiane, A | 1 |
| Kellett, S | 1 |
| Genest, J | 1 |
| Fürst, R | 1 |
| Zündorf, I | 1 |
| Catapano, AL | 1 |
| Farnier, M | 1 |
| Foody, JM | 1 |
| Toth, PP | 1 |
| Tomassini, JE | 1 |
| Brudi, P | 1 |
| Tershakovec, AM | 1 |
| deGoma, EM | 1 |
| Salavati, A | 1 |
| Shinohara, RT | 1 |
| Saboury, B | 1 |
| Pollan, L | 1 |
| Schoen, M | 1 |
| Torigian, DA | 1 |
| Mohler, ER | 1 |
| Dunbar, RL | 1 |
| Litt, HI | 1 |
| Woo, J | 1 |
| Rader, DJ | 1 |
| Alavi, A | 1 |
| Dubé, MP | 1 |
| Komarow, L | 1 |
| Fichtenbaum, CJ | 1 |
| Cadden, JJ | 1 |
| Overton, ET | 1 |
| Hodis, HN | 1 |
| Currier, JS | 1 |
| Stein, JH | 1 |
| Li, X | 1 |
| Wang, N | 1 |
| Yin, G | 1 |
| Ma, S | 1 |
| Fu, Y | 1 |
| Wei, C | 1 |
| Chen, Y | 1 |
| Xu, W | 1 |
| Su, G | 1 |
| Sun, G | 1 |
| Liu, H | 1 |
| Shu, L | 1 |
| Guo, L | 1 |
| Huang, C | 1 |
| Xu, J | 1 |
| Graff, EC | 1 |
| Fang, H | 1 |
| Wanders, D | 1 |
| Judd, RL | 1 |
| Naranjo, MC | 1 |
| Muriana, FJ | 1 |
| Nakamichi, R | 1 |
| Miranda, EP | 1 |
| Lobo, SM | 1 |
| Tristão, VR | 1 |
| Dalboni, MA | 1 |
| Quinto, BM | 1 |
| Batista, MC | 1 |
| Schuller-Levis, G | 1 |
| Gordon, RE | 1 |
| Park, SY | 1 |
| Park, E | 1 |
| Cho, KH | 1 |
| Kim, HJ | 1 |
| Rodriguez-Iturbe, B | 1 |
| Vaziri, ND | 1 |
| Stebbins, KJ | 1 |
| Broadhead, AR | 1 |
| Baccei, CS | 1 |
| Scott, JM | 1 |
| Truong, YP | 1 |
| Coate, H | 1 |
| Stock, NS | 1 |
| Santini, AM | 1 |
| Fagan, P | 1 |
| Prodanovich, P | 1 |
| Bain, G | 1 |
| Stearns, BA | 1 |
| King, CD | 1 |
| Hutchinson, JH | 1 |
| Prasit, P | 1 |
| Evans, JF | 1 |
| Lorrain, DS | 1 |
| Wu, BJ | 2 |
| Yan, L | 1 |
| Charlton, F | 1 |
| Witting, P | 1 |
| Barter, PJ | 2 |
| Rye, KA | 2 |
| Yvan-Charvet, L | 1 |
| Kling, J | 1 |
| Pagler, T | 1 |
| Li, H | 1 |
| Hubbard, B | 1 |
| Fisher, T | 1 |
| Sparrow, CP | 1 |
| Taggart, AK | 1 |
| Tall, AR | 1 |
| Reddy, KJ | 1 |
| Singh, M | 1 |
| Batsell, RR | 1 |
| Bangit, JR | 1 |
| Miraskar, RA | 1 |
| Zaheer, MS | 1 |
| Wi, J | 1 |
| Kim, JY | 1 |
| Park, S | 1 |
| Kang, SM | 1 |
| Jang, Y | 1 |
| Chung, N | 1 |
| Shim, WH | 1 |
| Cho, SY | 1 |
| Lee, SH | 1 |
| Ruparelia, N | 2 |
| Digby, JE | 2 |
| Choudhury, RP | 2 |
| Holzhäuser, E | 1 |
| Albrecht, C | 1 |
| Zhou, Q | 1 |
| Buttler, A | 1 |
| Preusch, MR | 1 |
| Blessing, E | 1 |
| Katus, HA | 1 |
| Bea, F | 1 |
| Chen, K | 1 |
| Martinez, F | 1 |
| Jefferson, A | 1 |
| Chai, J | 1 |
| Wamil, M | 1 |
| Greaves, DR | 1 |
| Tomono, S | 1 |
| Ohyama, Y | 1 |
| Uchiyama, T | 1 |
| Kuvin, JT | 2 |
| Karas, RH | 2 |
| LAI, G | 1 |
| DOMENJOZ, R | 1 |
| INDOVINA, I | 1 |
| CAUSI, N | 1 |
| SPAIN, DM | 1 |
| FASSBENDER, HG | 1 |
| WEISS, W | 1 |
| WEISS, N | 1 |
| REED, WB | 1 |
| KIERLAND, RR | 1 |
| CODE, CF | 1 |
| GOGLIA, G | 1 |
| HIEMEYER, V | 1 |
| FRANK, L | 1 |
| RAPP, Y | 1 |
| BIRO, L | 1 |
| GLICKMAN, FS | 1 |
| STOICHITA, M | 1 |
| REINHARDT, F | 1 |
| Ng, DS | 1 |
| Foley, SM | 1 |
| Parhofer, KG | 1 |
| Mitrofanov, VA | 1 |
| Ovchinnikova, NM | 1 |
| Belova, SV | 1 |
| Fedotova, MV | 1 |
| Gladkova, EV | 1 |
| Dave, DM | 1 |
| Sliney, KA | 1 |
| Mooney, P | 1 |
| Patel, AR | 1 |
| Kimmelstiel, CD | 1 |
| Rana, JS | 1 |
| Nieuwdorp, M | 1 |
| Jukema, JW | 1 |
| Kastelein, JJ | 1 |
| Carballo-Jane, E | 1 |
| Ciecko, T | 1 |
| Luell, S | 1 |
| Woods, JW | 1 |
| Zycband, EI | 1 |
| Waters, MG | 1 |
| Forrest, MJ | 1 |
| Thoenes, M | 1 |
| Oguchi, A | 1 |
| Nagamia, S | 1 |
| Vaccari, CS | 1 |
| Hammoud, R | 1 |
| Umpierrez, GE | 1 |
| Khan, BV | 1 |
| Penkowa, M | 1 |
| Giralt, M | 1 |
| Moos, T | 1 |
| Thomsen, PS | 1 |
| Hernández, J | 1 |
| Hidalgo, J | 1 |
| Schneede, J | 1 |
| Refsum, H | 1 |
| Ueland, PM | 1 |
| Wang, Q | 1 |
| Hyde, DM | 1 |
| Giri, SN | 1 |
| Williams, AC | 1 |
| Ramsden, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study[NCT00953667] | 400 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate[NCT01426438] | Phase 2 | 99 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART[NCT01683656] | Phase 4 | 4 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Withdrawal of IMP from the market. Data on risk-benefit ratio pending.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00953667)
Timeframe: Baseline ( -15 min, -5 min), and 1, 2, 4, 6, 12, 18, and 24 hours post LPS
| Intervention | mg/L (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CRP in EA males | Peak CRP in EA males | Baseline CRP in AA males | Peak CRP in AA males | Baseline CRP in EA females | Peak CRP in EA females | Baseline CRP in AA females | Peak CRP in AA females | |
| Niacin/Endotoxin | 0.34 | 17.8 | 0.54 | 14.25 | 0.62 | 15.9 | 0.71 | 10.8 |
(NCT00953667)
Timeframe: Baseline (-15 min, -5 min), and 1, 2, 4, 6, 12, 18, and 24 hours post LPS
| Intervention | pg/ml (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TNF-alpha in EA males (n=102) | Peak TNF-alpha in EA males (n=102) | Baseline TNF-alpha in AA males (n=41) | Peak TNF-alpha in AA males (n=41) | Baseline TNF-alpha in EA females (n=91) | Peak TNF-alpha in EA females (n=91) | Baseline TNF-alpha in AA females (n=60) | Peak TNF-alpha in AA females (n=60) | |
| Niacin/Endotoxin | 1.08 | 43.48 | 1.03 | 37.28 | 1.06 | 43.23 | 1.13 | 34.01 |
The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | % FMD (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.60 |
| Arm B: Fenofibrate | 0.50 |
Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | ug/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -0.6 |
| Arm B: Fenofibrate | 0.7 |
Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -9 |
| Arm B: Fenofibrate | -2 |
Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | ug/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.06 |
| Arm B: Fenofibrate | 0.06 |
Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -1.7 |
| Arm B: Fenofibrate | 4.3 |
Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | HOMA IR Score (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 1.3 |
| Arm B: Fenofibrate | 0.3 |
Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.1 |
| Arm B: Fenofibrate | 0.2 |
Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.9 |
| Arm B: Fenofibrate | -0.3 |
Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -1 |
| Arm B: Fenofibrate | 7 |
Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -17 |
| Arm B: Fenofibrate | -4 |
Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -176 |
| Arm B: Fenofibrate | -119 |
Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -65 |
| Arm B: Fenofibrate | -54 |
Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 3 |
| Arm B: Fenofibrate | 6.5 |
Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 16 |
| Arm B: Fenofibrate | 8 |
12 reviews available for niacin and Innate Inflammatory Response
| Article | Year |
|---|---|
Treatment options for low high-density lipoproteins.
Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Diabeti | 2014 |
Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress.
Topics: Animals; Anti-Inflammatory Agents; Capsaicin; Catechin; Colchicine; Curcumin; Humans; Imidazoles; In | 2014 |
Combination therapy in dyslipidemia: where are we now?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical T | 2014 |
Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2.
Topics: Animals; Atherosclerosis; Colitis; Diabetic Retinopathy; Humans; Inflammation; Mice; Neoplasms; Neur | 2016 |
Effects of niacin on atherosclerosis and vascular function.
Topics: Atherosclerosis; Endothelium, Vascular; Humans; Hypolipidemic Agents; Inflammation; Lipid Metabolism | 2011 |
[Insulin resistance induced by drugs, inflammation and stress].
Topics: Adrenergic beta-Antagonists; Benzothiadiazines; Contraceptives, Oral, Hormonal; Cyclosporins; Diabet | 2002 |
The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers.
Topics: Arteriosclerosis; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Disease Progre | 2003 |
Treating low HDL--from bench to bedside.
Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Disease; Endothelium, Vascular; Humans; Hype | 2004 |
Update on risk factors for atherosclerosis: the role of inflammation and apolipoprotein E.
Topics: Apolipoproteins E; Arteriosclerosis; Cholestyramine Resin; Diet, Fat-Restricted; Exercise; Genotype; | 2005 |
Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
Topics: Arteries; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Drug Evaluation; Humans; Hyperlipidem | 2005 |
Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Va | 2007 |
Biological and environmental determinants of plasma homocysteine.
Topics: Adult; Aged; Aging; Alcohol Drinking; Child; Cystathionine beta-Synthase; Diagnosis-Related Groups; | 2000 |
5 trials available for niacin and Innate Inflammatory Response
| Article | Year |
|---|---|
A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography.
Topics: Aorta; Aspirin; Atherosclerosis; Carotid Arteries; Double-Blind Method; Female; Fluorodeoxyglucose F | 2015 |
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipide | 2015 |
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Fibric Ac | 2010 |
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Co | 2006 |
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
Topics: Adult; Atherosclerosis; Biomarkers; Blood Glucose; Carotid Arteries; Cholesterol, HDL; Delayed-Actio | 2007 |
46 other studies available for niacin and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
GPR109A alleviate mastitis and enhances the blood milk barrier by activating AMPK/Nrf2 and autophagy.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cytokines; Epithelial Cells; Female; Gene Expression | 2021 |
Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation.
Topics: Allosteric Regulation; Animals; Colitis; GTP-Binding Protein alpha Subunits, Gi-Go; Inflammation; Ke | 2023 |
Immediate-release niacin and a monounsaturated fatty acid-rich meal on postprandial inflammation and monocyte characteristics in men with metabolic syndrome.
Topics: Dietary Fats; Fatty Acids; Fatty Acids, Monounsaturated; Humans; Inflammation; Male; Meals; Metaboli | 2023 |
Nicotinic Acid-Mediated Modulation of Metastasis-Associated Protein 1 Methylation and Inflammation in Brain Arteriovenous Malformation.
Topics: Arteriovenous Malformations; Brain; Cytokines; DNA Methylation; Endothelial Cells; Humans; Inflammat | 2023 |
Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A.
Topics: Animals; Anti-Inflammatory Agents; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Lipopolys | 2019 |
Anti-hypernociceptive and anti-inflammatory effects of JM-20: A novel hybrid neuroprotective compound.
Topics: Animals; Behavior, Animal; Benzodiazepines; Cell Movement; Inflammation; Male; Neuroprotective Agent | 2020 |
Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea.
Topics: Adolescent; Adult; Ascorbic Acid; Case-Control Studies; Diet; Dietary Carbohydrates; Dietary Fats; D | 2021 |
Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis.
Topics: Animals; Biomarkers; Biopsy; Body Weight; Colitis, Ulcerative; Cytokines; Disease Models, Animal; In | 2017 |
Diabetex: A novel approach for diabetic wound healing.
Topics: Alanine; Animals; Ascorbic Acid; Blood Coagulation; Blood Glucose; Collagen; Diabetes Mellitus, Expe | 2018 |
Hydroxycarboxylic Acid Receptor Ligands Modulate Proinflammatory Cytokine Expression in Human Macrophages and Adipocytes without Affecting Adipose Differentiation.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Atherosclerosis; Cells, Cultured; Cytokines; Gene Expressi | 2018 |
Vitamin D intervention does not improve vascular regeneration in diet-induced obese male mice with peripheral ischemia.
Topics: Animals; Cell Movement; Cell Proliferation; Diet; Endothelial Cells; Gene Expression Profiling; Hind | 2019 |
Race and gender variation in response to evoked inflammation.
Topics: Adolescent; Adult; Biomarkers; Black People; Cardiovascular Diseases; Endotoxemia; Ethnicity; Female | 2013 |
Niacin inhibits carrageenan-induced neutrophil migration in mice.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cell Adhesion; Chemokine CXCL1; Disease Models, Anim | 2013 |
Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood-brain barrier function in wild-type mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins A; Blood-Brain Barrier; Cyclooxyge | 2013 |
GPR109A Expression in the Murine Min6 Pancreatic Beta Cell Line, and Its Relation with Glucose Metabolism and Inflammation.
Topics: 3-Hydroxybutyric Acid; Animals; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplas | 2015 |
Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells.
Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Cy | 2015 |
Niacin and olive oil promote skewing to the M2 phenotype in bone marrow-derived macrophages of mice with metabolic syndrome.
Topics: Animals; Body Weight; Cholesterol; Cytokines; Diet; Dietary Fats, Unsaturated; Docosahexaenoic Acids | 2016 |
Action of nicotinic acid on the reversion of hypoxic-inflammatory link on 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cell Hypoxia; Hypoxia-Inducible Factor 1, alpha Subu | 2016 |
Protection of bleomycin-induced fibrosis and inflammation by taurine.
Topics: Animals; Bleomycin; Cell Movement; Chemotaxis; Chromatography, High Pressure Liquid; Cytoprotection; | 2009 |
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
Topics: Animals; Chemokine CCL2; Creatinine; Disease Models, Animal; Hypertension; Inflammation; Kidney Fail | 2009 |
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung.
Topics: Animals; Benzylamines; Cell Line; Cell Movement; Female; Guinea Pigs; Humans; In Vitro Techniques; I | 2010 |
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.
Topics: Animals; Anti-Inflammatory Agents; Aortic Diseases; Carotid Artery Diseases; Chemokine CCL2; Cyclic | 2010 |
Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Topics: Animals; Anti-Inflammatory Agents; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transpor | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Bi | 2010 |
Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Apolipoproteins E; Brachiocephalic Trunk; Female | 2011 |
Niacin inhibits vascular inflammation via the induction of heme oxygenase-1.
Topics: Animals; Atherosclerosis; Cells, Cultured; Coronary Vessels; Enzyme Induction; Heme Oxygenase-1; Hum | 2012 |
Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms.
Topics: Anti-Inflammatory Agents; Cell Adhesion; Cells, Cultured; Chemokine CCL2; Chemotaxis, Leukocyte; Cyc | 2012 |
[Case of polyserositis treated with isonicotinic acid hydrazide].
Topics: Chronic Disease; Inflammation; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Serositis | 1952 |
[Effects of isonicotinic acid hydrazide on the formalin inflammation and the dextran edema].
Topics: Dextrans; Edema; Formaldehyde; Inflammation; Isoniazid; Niacin; Nicotinic Acids; Respiratory Hyperse | 1952 |
[Metabolism of nicotinamide in man. II. Venous tolerance test in inflammatory processes].
Topics: Inflammation; Multiple Endocrine Neoplasia Type 2a; Niacin; Niacinamide; Veins | 1952 |
Effect of isoniazid on early acute inflammatory response in mice.
Topics: Animals; Inflammation; Isoniazid; Mice; Niacin; Nicotinic Acids | 1953 |
[Experimental studies on allergic-hyperergic inflammation].
Topics: Anti-Allergic Agents; Atropine; Histamine H1 Antagonists; Histidine; Hypersensitivity; Inflammation; | 1955 |
The skin response to a nicotinic acid ester: an acute phase reaction.
Topics: Acute-Phase Reaction; Furans; Inflammation; Niacin; Nicotinic Acids; Ointments | 1956 |
Nicotinic acid blood levels in relation to the skin response to a nicotinic acid ester ointment.
Topics: Blood; Furans; Inflammation; Niacin; Nicotinic Acids; Ointments | 1956 |
Vascular reactions in chronically inflamed skin. III. Action of histamine, the histamine releaser 48-80, and monoethanolamine nicotinate (nicamin).
Topics: Ethanolamine; Histamine; Histamine Agents; Histamine Release; Inflammation; Niacin; Nicotinic Acids; | 1958 |
[On a new medicinal combination in the percutaneous therapy of acute and chronic inflammation of the respiratory tract].
Topics: Balsams; Disease; Inflammation; Niacin; Nicotinic Acids; Respiration Disorders; Respiratory System; | 1962 |
[Comparative studies on the antiphlogistic effect of nicotinoamide-phenyl-dimethylpyrazolone and its combination with prednisone].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Antipyrine; Humans; Inflammation; Niacin; Niacin | 1963 |
INFLAMMATION MEDIATORS AND THE INFLAMMATORY REACTION.
Topics: Anti-Allergic Agents; Bradykinin; Capillary Permeability; Chlorpheniramine; Cyproheptadine; Fluoresc | 1964 |
[FIBRINOLYSIS, THROMBOLYSIS AND FIBRINOLYTIC TREATMENT].
Topics: Anticoagulants; Arteriosclerosis; Deoxyribonuclease I; Drug Therapy; Fibrinolysis; Inflammation; Nia | 1964 |
[Treatment of acute and chronic inflammation of the gallbladder and bile duct with bilamid].
Topics: Bile Ducts; Cholangitis; Cholecystitis; Humans; Inflammation; Niacin | 1959 |
Inflammatory degeneration of joint tissue in adjuvant arthritis after intraarticular treatment with the mixture of silver drug and nicotinic acid.
Topics: Animals; Arthritis, Experimental; Drug Synergism; Flow Cytometry; Glycosaminoglycans; Inflammation; | 2005 |
Potential role for epidermal Langerhans cells in nicotinic acid-induced vasodilatation in the mouse.
Topics: Animals; Epidermis; Hydrocortisone; Indomethacin; Inflammation; Langerhans Cells; Laser-Doppler Flow | 2007 |
Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice.
Topics: 6-Aminonicotinamide; Animals; Astrocytes; Blood-Brain Barrier; Bone Marrow Cells; Cell Death; Colori | 1999 |
Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Cell Membrane Permeability; Cricetinae; Drug Thera | 1992 |
Pellagra: A clue as to why energy failure causes diseases?
Topics: Animals; Biochemistry; Diet; Humans; Infections; Inflammation; Metabolism; Models, Biological; Model | 2007 |